VOGX Vogenx, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1903784 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets1.0%
Debt / equity0.00x
Current ratio98.33x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | — | — | — | — |
| R&D expense | $1.08M | $156,786 | — | $124,813 | $136,392 | — |
| SG&A expense | $703,736 | $198,598 | — | $177,664 | $174,268 | — |
| Net income | -$4.91M | -$384,430 | -$475,452 | -$284,407 | -$294,797 | -$356,619 |
| EPS (basic) | -0.47 | -0.07 | — | -0.05 | -0.05 | — |
| EPS (diluted) | -0.47 | -0.07 | — | -0.05 | -0.05 | — |
| Weighted avg. shares (diluted) | 10.40M | 5.45M | — | 5.45M | 5.45M | — |
| Balance sheet | ||||||
| Cash & equivalents | $5.13M | $193,017 | — | $234,348 | $390,276 | — |
| Short-term investments | $76.99M | — | — | — | — | — |
| Current assets | $82.84M | $1.41M | — | — | — | — |
| Total assets | $82.84M | $1.41M | — | — | — | — |
| Current liabilities | $842,470 | $3.19M | — | — | — | — |
| Total liabilities | $842,470 | $3.19M | — | — | — | — |
| Shareholders' equity | $82.00M | -$1.78M | -$1.40M | -$418,376 | -$136,590 | $155,586 |
| Shares outstanding | 14.86M | 5.26M | — | — | — | — |
| Cash flow statement | ||||||
| Operating cash flow | -$2.59M | — | — | -$155,928 | — | — |
| Financing cash flow | $84.51M | — | — | $0 | — | — |
| Stock-based compensation | $4,708 | — | — | $2,621 | — | — |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.